Tue, May 8, 2012
Mon, May 7, 2012

Matthew Harrison Upgraded (VRTX) to Hold and Increased Target to $51 on, May 8th, 2012

Matthew Harrison of Morgan Stanley, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold and Increased Target from $28 to $51 on, May 8th, 2012.

Matthew has made no other calls on VRTX in the last 4 months.



There is 1 other peer that has a rating on VRTX. Out of the 1 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $49 on, Wednesday, March 14th, 2012